The U.S. Food and Drug Administration recently issued a draft guidance titled, “Benefit-Risk Assessment for New Drug and Biological Products,” which aims to provide a clearer understanding how a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results